Project Summary/Abstract
The Gordon Research Conference (GRC) and Symposium (GRS) for "Radionuclide Theranostics for the
Management of Cancer", a rapidly emerging field in diagnostic and therapeutic oncology, will be held July 6-
12, 2024. The scientific goal of this meeting will be to address the challenges and advancements of
radionuclide theranostics in the field of cancer. The inaugural GRS component will target the preclinical
sciences whereas the GRC component will target the clinically translated science with ample time for
discussions. Our aim is to create the hybrid space for radioimmunobiology in cancer and attract a significant
number of attendees (250) including scientists, students, and physicians from academia and companies
developing Radionuclide Theranostics for a viable conference and creating the future community. The unique
format of GRC and GRS allowing participation by application and encouragement to share unpublished data
with fostering discussions within and between sessions creates the opportunity for formal and informal
interactions and collaborations that are likely to have significant and sustained impact on the field. We are
witnessing a fundamental transformation and unprecedented growth to offer precise antitumoral therapies and
diagnostics while increasing the awareness on quality of life with minimized toxicity and side effect profile.
Today, there are more than 100 pharmaceutical companies, over 250 active clinical trials using beta, alpha or
gamma emitting radionuclides that are supported by not only private but national laboratories and DOE
(department of energy). As clearly seen, the field of Radionuclide Theranostics depends on collaboration
between academia, federal and private organizations with the mutual aim of achieving improved patient
outcomes. Funds from the NIH R13 conference grant will be specifically targeted to promote participation in the
conference by women, under-represented minorities, people with disabilities and particularly graduate
students, postdoctoral fellows, and early career investigators.